Halozyme Therapeutics, a biopharmaceutical company developing and commercialising products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, has reported revenues of $3.4m for the third quarter ended 30 September 2010, compared to $3.03m for the same period in 2009.
Halozyme has posted a net loss of $12.4m for the third quarter 2010, or $0.13 loss per diluted share, compared to net loss of $13.91m, or $0.16 loss per diluted share, for the comparable period in 2009.
Halozyme’s operating loss was $12.43m, compared to $13.94m for the comparable period in 2009.
The company has posted revenue of $10.05m, for the nine months ended 30 September 2010, compared to $7.23m for the year ago period.
For the nine months ended 30 September 2010, Halozyme posted a net loss of $36.35m, or $0.39 loss per diluted share, compared to $45.7m, or $0.54 loss per diluted share, for the year ago period.
The company’s operating loss for the nine months ended 30 September 2010 was $36.37m, compared to $45.78m for the year ago period.
Halozyme’s president and CEO Jonathan Lim said that the company achieved further clinical advances during the third quarter as they began additional studies for the Ultrafast Insulin and PEGPH20 proprietary programs.
“In addition, we are excited by the continuing progress of our partners as Baxter and Roche presented positive data at medical meetings from their clinical trials for subcutaneous immunoglobulin and Herceptin SC, products that utilize our core rHuPH20 enzyme technology,” Lim said.
Halozyme’s Enhanze technology is a drug delivery platform designed to increase the absorption and dispersion of biologics.